| Attribute |
Value |
| 52 Week Change |
-0.5845467 |
| Address1 |
601 Genome Way |
| Address2 |
Suite 2001 |
| All Time High |
212.5 |
| All Time Low |
1.22 |
| Ask |
0.0 |
| Ask Size |
100 |
| Average Analyst Rating |
1.0 - Strong Buy |
| Average Daily Volume10 Day |
57,900 |
| Average Daily Volume3 Month |
98,026 |
| Average Volume |
98,026 |
| Average Volume10Days |
57,900 |
| Beta |
0.029 |
| Bid |
0.0 |
| Bid Size |
2,000 |
| Book Value |
0.852 |
| City |
Huntsville |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.05 |
| Current Ratio |
4.176 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
2.14 |
| Day Low |
2.0401 |
| Debt To Equity |
18.93 |
| Display Name |
Serina Therapeutics |
| Earnings Timestamp End |
1,754,654,400 |
| Earnings Timestamp Start |
1,754,305,140 |
| Ebitda |
-24,370,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.595 |
| Enterprise To Revenue |
111.507 |
| Enterprise Value |
14,495,885 |
| Eps Current Year |
-1.41 |
| Eps Forward |
-1.05 |
| Eps Trailing Twelve Months |
-2.0 |
| Esg Populated |
0 |
| Exchange |
ASE |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.85128 |
| Fifty Day Average Change |
0.19871998 |
| Fifty Day Average Change Percent |
0.10734194 |
| Fifty Two Week Change Percent |
-58.45467 |
| Fifty Two Week High |
7.92 |
| Fifty Two Week High Change |
-5.87 |
| Fifty Two Week High Change Percent |
-0.7411616 |
| Fifty Two Week Low |
1.22 |
| Fifty Two Week Low Change |
0.8299999 |
| Fifty Two Week Low Change Percent |
0.6803278 |
| Fifty Two Week Range |
1.22 - 7.92 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,543,501,800,000 |
| Float Shares |
8,408,201 |
| Forward Eps |
-1.05 |
| Forward P E |
-1.952381 |
| Free Cashflow |
-7,958,750 |
| Full Exchange Name |
NYSE American |
| Full Time Employees |
16 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-13,273,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.85962 |
| Held Percent Institutions |
0.09835 |
| Implied Shares Outstanding |
14,997,505 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,710,460,800 |
| Last Split Factor |
28:1000 |
| Long Business Summary |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama. |
| Long Name |
Serina Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
30,744,884 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_133692495 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-21,558,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
30,744,885 |
| Number Of Analyst Opinions |
2 |
| Open |
2.08 |
| Operating Cashflow |
-18,201,000 |
| Operating Margins |
-188.03076 |
| Payout Ratio |
0.0 |
| Phone |
256 327 9630 |
| Pre Market Change |
-0.07620001 |
| Pre Market Change Percent |
-3.7170737 |
| Pre Market Price |
1.9738 |
| Pre Market Time |
1,784,025,103 |
| Previous Close |
2.14 |
| Price Eps Current Year |
-1.4539007 |
| Price Hint |
4 |
| Price To Book |
2.4061031 |
| Price To Sales Trailing12 Months |
236.49911 |
| Profit Margins |
0.0 |
| Quick Ratio |
3.868 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.0 |
| Region |
US |
| Regular Market Change |
-0.0900002 |
| Regular Market Change Percent |
-4.20561 |
| Regular Market Day High |
2.14 |
| Regular Market Day Low |
2.0401 |
| Regular Market Day Range |
2.0401 - 2.14 |
| Regular Market Open |
2.08 |
| Regular Market Previous Close |
2.14 |
| Regular Market Price |
2.05 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
36,933 |
| Return On Assets |
-0.89788 |
| Return On Equity |
-2.21932 |
| Revenue Per Share |
0.012 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
14,997,505 |
| Shares Percent Shares Out |
0.019 |
| Shares Short |
285,430 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
345,042 |
| Short Name |
Serina Therapeutics, Inc. |
| Short Percent Of Float |
0.0248 |
| Short Ratio |
2.12 |
| Source Interval |
15 |
| State |
AL |
| Symbol |
SER |
| Target High Price |
11.0 |
| Target Low Price |
8.0 |
| Target Mean Price |
9.5 |
| Target Median Price |
9.5 |
| Total Cash |
24,526,000 |
| Total Cash Per Share |
1.635 |
| Total Debt |
3,337,000 |
| Total Revenue |
130,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.0 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
2.770895 |
| Two Hundred Day Average Change |
-0.72089505 |
| Two Hundred Day Average Change Percent |
-0.26016685 |
| Type Disp |
Equity |
| Volume |
36,933 |
| Website |
https://serinatherapeutics.com |
| Zip |
35,806 |